Biophytis S.A. (ALBPS.PA)
EUR 0.33
(0.92%)
EUR 0.33
(0.92%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -17.02 Million EUR | 29.69% |
| 2022 | -24.21 Million EUR | 22.29% |
| 2021 | -31.16 Million EUR | -22.13% |
| 2020 | -25.51 Million EUR | -34.68% |
| 2019 | -18.94 Million EUR | -35.45% |
| 2018 | -13.98 Million EUR | -22.61% |
| 2017 | -11.4 Million EUR | -43.42% |
| 2016 | -7.95 Million EUR | -52.03% |
| 2015 | -5.23 Million EUR | -638.0% |
| 2014 | -708.93 Thousand EUR | -35.93% |
| 2013 | -521.54 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.9 Million EUR | 0.0% |
| 2024 Q1 | -2.9 Million EUR | 37.25% |
| 2023 Q2 | -3.88 Million EUR | 0.0% |
| 2023 Q3 | -4.63 Million EUR | -19.29% |
| 2023 FY | -17.02 Million EUR | 24.98% |
| 2023 Q4 | -4.63 Million EUR | 0.0% |
| 2023 Q1 | -3.88 Million EUR | 34.3% |
| 2022 Q2 | -6.19 Million EUR | 0.0% |
| 2022 Q1 | -6.19 Million EUR | 30.81% |
| 2022 FY | -22.69 Million EUR | 32.31% |
| 2022 Q3 | -5.9 Million EUR | 4.68% |
| 2022 Q4 | -5.9 Million EUR | 0.0% |
| 2021 Q4 | -8.95 Million EUR | 0.0% |
| 2021 FY | -33.52 Million EUR | -56.46% |
| 2021 Q1 | -6.62 Million EUR | -12.07% |
| 2021 Q2 | -6.62 Million EUR | 0.0% |
| 2021 Q3 | -8.95 Million EUR | -35.28% |
| 2020 Q4 | -5.9 Million EUR | 0.0% |
| 2020 Q1 | -6.84 Million EUR | -56.6% |
| 2020 Q3 | -5.9 Million EUR | 13.73% |
| 2020 Q2 | -6.84 Million EUR | 0.0% |
| 2020 FY | -21.42 Million EUR | -20.46% |
| 2019 Q1 | -3.72 Million EUR | 10.16% |
| 2019 FY | -17.78 Million EUR | -27.18% |
| 2019 Q4 | -4.37 Million EUR | 0.0% |
| 2019 Q3 | -4.37 Million EUR | 32.41% |
| 2019 Q2 | -6.47 Million EUR | -73.62% |
| 2018 Q3 | -4.14 Million EUR | -48.91% |
| 2018 Q2 | -2.78 Million EUR | 4.06% |
| 2018 Q1 | -2.9 Million EUR | 9.18% |
| 2018 FY | -13.98 Million EUR | -22.6% |
| 2018 Q4 | -4.14 Million EUR | 0.0% |
| 2017 Q2 | -2.5 Million EUR | 0.0% |
| 2017 Q3 | -3.19 Million EUR | -27.57% |
| 2017 Q4 | -3.19 Million EUR | 0.0% |
| 2017 FY | -11.4 Million EUR | -43.44% |
| 2017 Q1 | -2.5 Million EUR | -18.4% |
| 2016 Q4 | -2.11 Million EUR | 0.0% |
| 2016 Q3 | -2.11 Million EUR | -13.82% |
| 2016 Q1 | -1.86 Million EUR | -6.26% |
| 2016 FY | -7.95 Million EUR | -141.9% |
| 2016 Q2 | -1.86 Million EUR | 0.0% |
| 2015 Q1 | -865.5 Thousand EUR | -352.05% |
| 2015 Q2 | -865.5 Thousand EUR | 0.0% |
| 2015 Q4 | -1.75 Million EUR | 0.0% |
| 2015 FY | -3.28 Million EUR | -363.82% |
| 2015 Q3 | -1.75 Million EUR | -102.25% |
| 2014 Q4 | -191.46 Thousand EUR | 0.0% |
| 2014 Q2 | -163.01 Thousand EUR | 0.0% |
| 2014 Q1 | -163.01 Thousand EUR | 0.0% |
| 2014 FY | -708.93 Thousand EUR | -35.93% |
| 2014 Q3 | -191.46 Thousand EUR | -17.45% |
| 2013 FY | -521.54 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -383.968% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 88.476% |
| Adocia SA | -21.16 Million EUR | 19.544% |
| Aelis Farma SA | -5.07 Million EUR | -235.289% |
| Advicenne S.A. | -7.03 Million EUR | -142.156% |
| genOway Société anonyme | 1.56 Million EUR | 1186.136% |
| IntegraGen SA | -171.39 Thousand EUR | -9833.547% |
| Medesis Pharma S.A. | -3.95 Million EUR | -330.005% |
| Neovacs S.A. | -8.74 Million EUR | -94.729% |
| NFL Biosciences SA | -3.74 Million EUR | -354.575% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 21605.892% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -436.937% |
| Sensorion SA | -22.06 Million EUR | 22.831% |
| Theranexus Société Anonyme | -6.82 Million EUR | -149.357% |
| TME Pharma N.V. | -6.73 Million EUR | -152.761% |
| Valbiotis SA | -7.36 Million EUR | -131.08% |
| TheraVet SA | -1.57 Million EUR | -983.97% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 16.309% |
| argenx SE | -272.91 Million EUR | 93.761% |
| BioSenic S.A. | -28.77 Million EUR | 40.837% |
| Celyad Oncology SA | -8.44 Million EUR | -101.539% |
| DBV Technologies S.A. | -67.26 Million EUR | 74.69% |
| Galapagos NV | 211.69 Million EUR | 108.043% |
| Genfit S.A. | -28.89 Million EUR | 41.074% |
| GeNeuro SA | -14.75 Million EUR | -15.376% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -10.702% |
| Innate Pharma S.A. | -7.57 Million EUR | -124.914% |
| Inventiva S.A. | -110.42 Million EUR | 84.582% |
| MaaT Pharma SA | -19.71 Million EUR | 13.648% |
| MedinCell S.A. | -25.03 Million EUR | 31.999% |
| Nanobiotix S.A. | -39.7 Million EUR | 57.113% |
| Onward Medical N.V. | -36.18 Million EUR | 52.942% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -407.793% |
| OSE Immunotherapeutics SA | -23 Million EUR | 25.984% |
| Oxurion NV | -18.96 Million EUR | 10.243% |
| Pharming Group N.V. | -9.75 Million EUR | -74.508% |
| Poxel S.A. | -35.09 Million EUR | 51.479% |
| GenSight Biologics S.A. | -26.22 Million EUR | 35.065% |
| Transgene SA | -22.32 Million EUR | 23.746% |
| Financière de Tubize SA | 88.15 Million EUR | 119.315% |
| UCB SA | 343 Million EUR | 104.964% |
| Valneva SE | -101.42 Million EUR | 83.214% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 39.927% |